Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2).
Saved in:
| Title: | Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2). |
|---|---|
| Authors: | Wiendl, Heinz1 (AUTHOR) heinz.wiendl@ukmuenster.de, Foley, John2 (AUTHOR), Defer, Gilles3 (AUTHOR), Zhovtis Ryerson, Lana4 (AUTHOR), Cohen, Jeffrey A.5 (AUTHOR), Arnold, Douglas L.6 (AUTHOR), Butzkueven, Helmut7 (AUTHOR), Cutter, Gary R.8 (AUTHOR), Giovannoni, Gavin9 (AUTHOR), Killestein, Joep10 (AUTHOR), Domingo-Horne, Rose11 (AUTHOR), Toukam, Marie11 (AUTHOR), Nunn, Aimie12 (AUTHOR), Maghzi, Amir-Hadi11 (AUTHOR), Kuhelj, Robert13 (AUTHOR), Lasky, Tyler11 (AUTHOR) |
| Source: | Neurology & Therapy. Oct2024, Vol. 13 Issue 5, p1385-1401. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938253 |
|---|---|
| DOI: | 10.1007/s40120-024-00647-0 |
